Please ensure Javascript is enabled for purposes of website accessibility

Vertex Pharmaceuticals Picks Between "Sirloin Steak and Filet Mignon"

By Brian Orelli, PhD - Feb 1, 2018 at 4:17PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Solid fourth-quarter earnings get topped off by impressive phase 2 data for the biotech's next-generation cystic fibrosis drugs.

Vertex Pharmaceuticals (VRTX 1.96%) rounded out 2017 on a high note with fourth-quarter sales of its cystic fibrosis franchise up 37% year over year, besting the 29% increase when looking at the entire year.

And on the pipeline front, the company announced impressive phase 2 data for its next-generation triple combinations with plans to bring two combinations into phase 3 development, checking off one of the items on its 2018 to-do list.

Vertex results: The raw numbers 

Metric

Q4 2017

Q4 2016

Year-Over-Year Change

Revenue

$651.6 million

$458.7 million

42%

Income from operations

$125.7 million

$39.6 million

217%

Earnings per share (EPS)

$0.39

$0.13

200%

Adjusted EPS

$0.61

$0.35

74%

Data source: Vertex Pharmaceuticals.

What happened with Vertex this quarter?

  • Revenue was boosted by a $25 million milestone payment from Johnson & Johnson for the start of a phase 3 clinical trial testing flu-treatment pimodivir.
  • Even excluding that boost, cystic fibrosis drug sales looked good with Orkambi increasing 32% and Kalydeco up 44% year over year. Expanded approvals for both drugs in younger patients have helped drive sales in the U.S. Abroad, growth is being driven by increased reimbursement in various countries.
  • In December, data from a phase 3 trial showed Kalydeco was helping patients aged 1 to 2. Vertex plans to submit the data to regulators this quarter to gain expanded approval for toddlers.
  • In January, after the quarter ended, the company gained approval in Europe to treat children ages 6 through 11 with Orkambi, setting up additional sales in the coming quarters.
  • Vertex and its partner CRISPR Therapeutics (CRSP 4.97%) announced plans to develop CTX001, a gene editing treatment for two blood diseases, beta-thalassemia and sickle cell disease. Separate phase 1/2 trials for both diseases are expected to begin this year.
  • In conjunction with the earnings release, Vertex released impressive data for its next-generation cystic fibrosis triple combinations containing VX-659 and VX-445. Vertex plans to start two phase 3 trials testing VX-659 in combination with tezacaftor and ivacaftor in the first half of 2018. A phase 3 program testing VX-445 with tezacaftor and VX-561, which is a once-daily version of ivacaftor, will start in the middle of the year, assuming positive phase 2 data for that combination, which is due out in the first half of the year.
  • The board authorized a $500 million repurchase of stock through the end of 2019.
Paper on clipboard with Cystic Fibrosis written on it surrounded by medication and a stethoscope

Image source: Getty Images.

What management had to say

Vertex had four different triple combinations to choose from, but as chairman, president, and CEO Jeff Leiden pointed out, the data for all four were promising. "The good news is they all look very, very good, so we are picking a bit between sirloin steak and filet mignon here," Leiden said.

Leiden also explained why the company is going to test both VX-659 and VX-445 in phase III trials, rather than just one of them. "We're taking two forward because that's one way of modifying one risk, and that's the risk of some rare off-target toxicity due to the next-gen corrector in one of these regimens and obviously by taking two forward, we mitigate that risk," Leiden said.

The same principle holds for why only one of them will be tested with VX-561, which Leiden refers to by its other nickname, d-Iva. "And so I would hate to put all my eggs in that basket and find out there is some very rare tolerability or safety issue with d-Iva that would set both programs back," Leiden said.

Looking forward

While the triple combinations are preparing for phase III development, Vertex still has one more potential approval with the combination of tezacaftor and ivacaftor, which the FDA is expected to rule on by the end of this month.

Given the pending application, management smartly decided to wait on issuing 2018 revenue guidance. While an approval seems extremely likely given the data, rolling back guidance would just add insult to injury if the FDA issued a rejection or delayed its decision, so there's no harm in waiting.

Investors should also keep in mind that the combination is likely to result in patients switching from Orkambi and Kalydeco to tezacaftor/ivacaftor, so total overall cystic fibrosis sales will be more important to watch than the moving parts of the three individual drugs.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
VRTX
$287.32 (1.96%) $5.53
CRISPR Therapeutics Stock Quote
CRISPR Therapeutics
CRSP
$63.79 (4.97%) $3.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.